Use of FEIBA for invasive or surgical procedures in patients with severe hemophilia A or B with inhibitors

Journal of Pediatric Hematology/Oncology

Volumn 29, Issue 4, 2007, Pages 216-221

  Stine, Kimo C ^a   Shrum, Dixie ^a   Becton, David L ^a  

^a ARKANSAS CHILDREN S HOSPITAL   (United States)

Author keywords

FEIBA; Hemophilia; Inhibitors; Surgery

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; AMINOCAPROIC ACID; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; FIBRINOGEN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9;

ADOLESCENT; ADULT; ANTIBODY TITER; ARTICLE; BLEEDING; CATHETER COMPLICATION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEMOPHILIA A; HEMOPHILIA B; HEMOSTASIS; HUMAN; MALE; MONOTHERAPY; POSTOPERATIVE CARE; PRIORITY JOURNAL; RISK ASSESSMENT; SINGLE DRUG DOSE; SURGICAL TECHNIQUE;

ADOLESCENT; ADULT; BLOOD COAGULATION FACTOR INHIBITORS; BLOOD COAGULATION FACTORS; BLOOD LOSS, SURGICAL; CHILD, PRESCHOOL; HEMOPHILIA A; HEMOPHILIA B; HEMOSTASIS; HEMOSTASIS, SURGICAL; HUMANS; INFANT; MALE;

EID: 34247169953     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e318041f101     Document Type: Article

References (33)

1. Goudemand J, Tagariello G, Lopaciuk F. Cases of surgery in high-responder haemophilia patients. Haemophilia. 2004;10(suppl 2):46-49.
2. Tjønnfjord GE, Brinch L, Gedde-Dahl G, et al. Activated prothrombin complex concentrate (FEIBAs) treatment during surgery in patients with inhibitors to FVIII/IX. Haemophilia. 2004;10:174-178.
3. Negrier C, Goudemand J, Sultan Y, et al., the French FEIBA Study Group. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. Thromb Haemost. 1997;77:1113-1119.
4. Quintana-Molina M, Martínez-Bahamonde F, González- García E, et al. Surgery in haemophilic patients with inhibitor: 20 years of experience. Haemophilia. 2004;10(suppl 2):30-40.
5. DiMichele D, Négrier C. A retrospective postlicensure survey of FEIBA efficacy and safety. Haemophilia. 2006;12:352-362.
6. FEIBA VH [package insert]. Westlake Village. Calif: Baxter Healthcare Corporation; 2001.
7. Hilgartner M, Aledort L, Andes A, et al. Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients. FEIBA Study Group. Transfusion. 1990;30:626-630.
8. Hilgartner MW, Knatterud GL, the FEIBA Study Group. The use of factor eight inhibitor by-passing activity (FEIBA immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors. Blood. 1983;61:36-40.
9. Aledort L. Inhibitors in hemophilia patents. Current status and management. Am J Hematol. 1994;47:208-217.
10. Ehrlich HJ, Henzl MJ, Gomperts ED. Safety of factor VIII inhibitor bypass activity (FEIBA®): 10-year compilation of thrombotic adverse events. Haemophilia. 2002;8:83-90.
11. Aledort LM. Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. J Thromb Haemost. 2004;2:1700-1708.
12. Leissinger CA. Prevention of bleeds in hemophilia patients with inhibitors: emerging data and clinical direction. Am J Hematol. 2004;77:187-193.
13. Ho AY, Height SE, Smith MP. Immune tolerance therapy for haemophilia. Drugs. 2000;60:547-554.
14. Sieger L, Aledort L. Inhibitor challenges in the paediatric setting. Haemophilia. 2006;12:106-107.
15. Turecek PL, Varadi K, Gritsch H, et al. FEIBA: mode of action. Haemophilia. 2004;10(suppl 2):3-9.
16. Hayashi T, Tanaka I, Shima M, et al. Unresponsiveness to factor VIII inhibitor bypassing agents during haemostatic treatment for life-threatening massive bleeding in a patient with haemophilia A and a high responding inhibitor. Haemophilia. 2004;10:397-400.
17. Lindley CM, Sawyer WT, Macik BG, et al. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther. 1994;55:638-648.
18. Goddard N. Case studies: orthopaedic surgery in adult patients with haemophilia A with inhibitors. Haemophilia. 2005;11(suppl 1):32-37.
19. Parameswaran R, Shapiro AD, Gill JC, et al., HTRS Registry Investigators. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry. Haemophilia. 2005;11:100-106.
20. NovoSeven [package insert]. Bagsvaerd. Denmark: NovoNordisk Inc; 2005.
21. Rodriguez-Merchan EC, Wiedel JD, Wallny T, et al. Elective orthopaedic surgery for inhibitor patients. Haemophilia. 2003;9:625-631.
22. Ingerslev J. Efficacy and safety of recombinant factor VIIa in the prophylaxis of bleeding in various surgical procedures in hemophilic patients with factor VIII and factor IX inhibitors. Semin Thromb Hemost. 2000;26:425-432.
23. Schneiderman J, Nugent DJ, Young G. Sequential therapy with activated prothrombin complex concentrate and recombinant factor VIIa in patients with severe haemophilia and inhibitors. Haemophilia. 2004;10:347-351.
24. Key NS, Christie B, Henderson N, et al. Possible synergy between recombinant factor VIIa and prothrombin complex concentrate in hemophilia therapy. Thromb Haemost. 2002;88:60-65.
25. Bui JD, Despotis GD, Trulock EP, et al. Fatal thrombosis after administration of activated prothrombin complex concentrates in a patient supported by extracorporeal membrane oxygenation who had received activated recombinant factor VII. J Thorac Cardiovasc Surg. 2002;124:852-854.
26. Rosenfeld SB, Watkinson KK, Thompson BH, et al. Pulmonary embolism after sequential use of recombinant factor VIIa and activated prothrombin complex concentrate in a factor VIII inhibitor patient [Letter]. Thromb Haemost. 2002;87:925-926.
27. Ghosh K, Shetty S, Jijina F, et al. Role of epsilon amino caproic acid in the management of haemophilic patients with inhibitors. Haemophilia. 2004;10:58-62.
28. Steinberg SE, Levin J, Bell WR. Evidence that less replacement therapy is required for dental extractions in haemophiliacs. Am J Haematol. 1984;16:1-13.
29. Jackson MR. Fibrin sealants in surgical practice: an overview. Am J Surg. 2001;182(suppl 2):1S-7S.
30. Valentino LA, Kapoor M. Central venous access devices in patients with hemophilia. Expert Rev Med Device. 2005;2:699-711.
31. Ewenstein BM, Valentino LA, Journeycake JM, et al. Consensus recommendations for use of central venous access devices in haemophilia. Haemophilia. 2004;10:629-648.
32. Carcao MD, Connolly BL, Chait P, et al. Central venous catheter-related thrombosis presenting as superior vena cava syndrome in a haemophilic patient with inhibitors. Haemophilia. 2003;9:578-583.
33. DiMichele DM, Kroner BL, North American Immune Tolerance Study Group. The North American Immune Tolerance Registry: practices, outcomes, outcome predictors. Thromb Haemost. 2002;87:52-57.